Login to Your Account

Start-up Mnemosyne's Series A Raises $5.4M for CNS Platform

By Marie Powers
Staff Writer

Thursday, February 16, 2012
Mnemosyne Pharmaceuticals Inc., an emerging biotech targeting central nervous system (CNS) disorders, raised $5.4 million in a Series A financing to advance its work on a class of molecules known as subunit selective NMDA receptor modulators (SNRMs).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription